Evaluation of Fenofibrate on Radiation-induced Skin Injury

Status Not yet recruiting

Clinical Trial Summary

Fenofibrate is a specific ligand for PPARα, which has been used for the treatment of hypercholesterolemia, hypertriglyceridemia, diabetes and cardiovascular diseases for long time. Fenofibrate reduces low-density lipoprotein (LDL), very low density lipoprotein (VLDL) and triglyceride levels, while increases high-density lipoprotein (HDL) levels. PPARα has also shown antioxidant and anti-inflammatory properties. Fenofibrate confers cytoprotective effect against myocardial ischemia-reperfusion (I/R) injury in rats by suppressing cell apoptosis and ameliorates age-related renal injury through the activation of AMPK and SIRT1 signaling. However, the safety and effectiveness of fenofibrate on the progression of radiation-induced skin injury remain unknown. The purpose of this study is to determine whether topical application of fenofibrate is safe and effective for radiation-induced skin injury.

Clinical Trial Description

Radiation-induced skin injury is a significant side effect of ionizing radiation delivered to the skin during cancer treatment as well as a result of other exposure to radiation. The skin is one of radiosensitive organ systems in human body because it is a continuously renewing organ containing rapidly proliferating and maturing cells. Ionizing radiation promotes reactive nitrogen and oxygen species (RNS/ROS) production due to radiolysis of water and direct ionization of target molecules, which result in oxidative damage and skin injuries. It is considered that ~95 % of cancer patients receiving radiation therapy will develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation. Radiation-induced skin injury negatively affects the process of radiotherapy and the quality of patients' life. Despite substantial improvements in radiation technology, radiation-induced skin toxicity is still a concerning problem. The purpose of this study is to determine whether topical application of fenofibrate is safe and effective for radiation-induced skin injury. ;

Study Design

Related Conditions & MeSH terms

Radiodermatitis

Clinical Trial Details

NCT number	NCT03557983
Study type	Interventional
Source	Second Affiliated Hospital of Soochow University
Contact	Shuyu Zhang, A/Prof.
Phone	86+15851417273
Email	zhang.shuyu@hotmail.com
Status	Not yet recruiting
Phase	N/A
Start date	June 13, 2018
Completion date	April 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04059809` - Photobiomodulation for Breast Cancer Radiodermatitis	Phase 2/Phase 3
Withdrawn	`NCT04593914` - A Novel Skin Barrier Protectant for Acute Radiodermatitis	N/A
Completed	`NCT06133218` - Patient Reported Outcomes Using Mepitel Film During Radiotherapy	N/A
Enrolling by invitation	`NCT02289365` - Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients	Phase 2
Completed	`NCT04483856` - Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.	N/A
Completed	`NCT02922244` - Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients	N/A
Recruiting	`NCT05886673` - Development of a Protective Cream Against Radiodermatitis Caused by Radiotherapy.	N/A
Withdrawn	`NCT01544504` - Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy	Phase 1/Phase 2
Completed	`NCT03255980` - Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®	N/A
Completed	`NCT02247830` - Management Radiodermatitis in Patients With Breast or Head and Neck Cancer	Phase 3
Terminated	`NCT01367990` - Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy	Phase 1
Completed	`NCT03924011` - Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy	N/A
Terminated	`NCT01263366` - Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients	Phase 1
Not yet recruiting	`NCT04617730` - Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.	Phase 1/Phase 2
Not yet recruiting	`NCT05535452` - Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy	N/A
Completed	`NCT04239560` - Preventive Effect of Boron-based Gel on Radiation Dermatitis	Phase 3
Completed	`NCT02249884` - Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis	Phase 2
Withdrawn	`NCT04692389` - Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.	N/A
Enrolling by invitation	`NCT04067310` - Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.	N/A
Enrolling by invitation	`NCT02251392` - Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.